Compare NGL & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | TYRA |
|---|---|---|
| Founded | 1940 | 2018 |
| Country | United States | United States |
| Employees | 569 | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2021 |
| Metric | NGL | TYRA |
|---|---|---|
| Price | $11.57 | $37.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $44.63 |
| AVG Volume (30 Days) | 230.3K | ★ 1.1M |
| Earning Date | 02-03-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $366.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.64 | $6.42 |
| 52 Week High | $13.00 | $38.53 |
| Indicator | NGL | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 68.00 |
| Support Level | $11.18 | $30.10 |
| Resistance Level | $13.00 | N/A |
| Average True Range (ATR) | 0.53 | 2.31 |
| MACD | -0.08 | 0.24 |
| Stochastic Oscillator | 31.75 | 92.17 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.